An mRNA-based FimH nanoparticle vaccine against uropathogenic Escherichia coli confers protection in a mouse model of recurrent urinary tract infection
Abstract
Background Increasing antimicrobial resistance and the high health and economic burden of frequent, recurring urinary tract infections (rUTIs) drive the need for an efficacious UTI vaccine. Most UTIs are caused by uropathogenic E. coli (UPEC) expressing the virulence factor FimH, which mediates bladder colonisation. We have developed a lipid nanoparticle (LNP) mRNA vaccine, FimHDG-Ferritin, as a UPEC vaccine candidate. Methods FimHDG-Ferritin mRNA constructs were introduced into HeLa cells through mRNA-transfection to assess the generation of immune-accessible protein nanoparticles (PNPs) in vitro by native polyacrylamide gel electrophoresis and negative stain electron microscopy. Following this, induction of humoral and cellular responses were evaluated in female BALB/c AnNRj mice and Wistar rats following either 2 or 3 intramuscular administrations of the FimHDG-Ferritin mRNA vaccine. Finally, protective efficacy was assessed in a clinically relevant mouse model of rUTI. Results In vitro PNP formation of the FimHDG-Ferritin fusion protein with intact functional epitopes was confirmed. Immunogenicity was demonstrated in mice and rats; equivalent functional antibody levels were raised against homologous and heterologous UPEC strains. In a rUTI mouse model, FimHDG-Ferritin mRNA vaccine administration induced the highest levels of functional antibodies among protein subunit comparators and significantly reduced bladder bacterial load versus negative controls. Conclusion These…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.